Wenger Vieli with Xeltis on EUR 50 million funding round
Wenger Vieli advised vascular implants specialist Xeltis on its financing round, raising approximately EUR 50 million. The sum includes up to EUR 37.5 million from the European Investment Bank (EIB) and EUR 10 million from existing shareholders such as EQT Life Sciences and Invest-NL.
The medtech company plans to utilyse the proceeds to debut a new type of implant that provides reliable blood access for patients undergoing kidney dialysis.
The Wenger Vieli team
Partner Beat Speck (corporate/M&A, pictured) led the Wenger Vieli team on the matter, working alongside counsels Jonas Bühlmann (tax) and Micha Schilling (financing), as well as associates Fabienne Nufer (corporate/M&A) and Dario Schönbächler (corporate/M&A).
